Could a cancer drug also fight wasting? tiny trial aims to find out

NCT ID NCT07146893

Not yet recruiting Symptom relief Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with regular weight checks and questionnaires. The goal is to see if weight stabilizes or improves, and if the drug is practical to take.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selpercatinib (RETEVMO), a drug taken orally twice daily
What this could lead to: If it works, this could point toward a treatment for cancer-related weight loss and poor appetite, improving quality of life.
What could go wrong: This is a very early, small feasibility study with only 7 participants. It may not show clear benefit, and side effects of selpercatinib are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA-ANOREXIA SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA-ANOREXIA SYNDROME

Contacts and locations

Locations

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.